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Peptide synthesis and characterization
All peptides were synthesized using an automatic Prelude 
Thiolated AMPs
To incorporate a thiol group at the C-terminus a cysteamine 2-chlorotrityl resin (Novabiochem, 01-64-0107) was used as solid support.
Peptide cleavage was done by treating the resin with 94% TFA, 2.5% TIS, 2.5% ethanedithiol (EDT, Fluka, 02390) and 1% water for 3 h. Peptide work up was done as with described above.
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Npys-modified histidine-rich vector peptides
In order to ensure that the correct (asymmetrical) disulfide bond is formed between the two components of the conjugate, one of the peptides' cysteine thiol-containing side chain had to be protected/activated. This is routinely achieved by the Npys-group and in this study a slightly modified version of Ghosh and Fan was used.
Following the completion of the peptide, the peptidyl-resin was treated with the following a cleavage cocktail composing of 95% TFA, 2.5% water, 2.5% TIS and 7 eq 2,2-dithio-bis(5-nitropyridine) (DTNP, Sigma-Aldrich, 158194) for 3 h. 
HPLC purification
All crude peptides were purified using preparative HPLC (Waters Autoprep: PAD Detector 2998, Binary pump 2545, Sample manager 2767).
A XSelect CSH column (C18, 5µm, 19 x 250mm) were used. Both mobile phases (water and acetonitrile) contained 0.1% TFA. The flow rate was 20 mL/min. The minimum purity of all peptides were 95% as determined by UPLC-PDA analyses.
Purity and molecular weight determination
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The purity of synthesized peptides was determined using (i) a Waters Acuity H-class UPLC with (ii) a Waters Acquity BEH C18 column 2.1x50 mm with 1.7 µm particles, and (iii) PDA detector with detection set at 200-500 nm, (iv) having a flow rate of 1 mL/min and gradient of 5 -95 %B over 10 min, and (v) where mobile phase A is water with 0.1% TFA and B is acetonitrile with 0.1% TFA.
The correct molecular weight of the compounds was determined using (i) a Waters Acuity I-class UPLC with (ii) a Waters Acquity BEH C18 column 2.1x100 mm with 1.7 µm particles column, and (iii) Waters XEVO Q-ToF G2 mass spectrometer, with the tune method set at capillary 0. RPMI-1640 medium (Sigma Aldrich, R8758) was used to prepare peptide dilution series (10-500 µg/mL), each concentration was done in triplicate. The pH of the assay-medium was 7.4, and potential changes in pH during the assay was monitored visually by inspecting the color of the assay-medium which should stay red throughout the experiment.
Each experiment was done at least in dublicate. To simulate elevated zinc levels found at angiogenic sites the media was adjusted with 50 µM ZnCl 2 . For negative controls the same media without peptide was used. For positive controls 1% Triton X-100 (Sigma Aldrich, T8787) was added to the media. A pilot study showed that incubation with ZnCl 2 is not toxic to DU-145 cells within the concentrations and incubation times used. A pilot study showed that incubation with DTNB is not toxic to DU-145 cells within the concentrations and incubation times used. All peptides were prepared as TFA salts and since the peptides contain a high number of basic amino acids with TFA counterions, TFA content were taken into account when determining IC 50 values. Although net peptide content was not empirically determined it is expected that the freeze dried material will contain a significant amount of TFA, see Table S1 . Therefore, MW values, adjusted for theoretical TFA content, were used in calculating IC 50 values. 
S18
Linker reduction assay
The stability of two disulfide peptides toward reduced glutathione (GSH) was determined in a kinetic assay. The peptides were dissolved in water to yield a stock solution of 1 mg/mL. Two different
targetide:GSH ratios were tested to simulate GSH concentrations found in plasma (1:10) and the cytosol (1:100). The peptides were diluted with 100 mM Tris (pH 7.6) to 50 µM working solutions right before the start of the reaction. A 10 mM GSH (Sigma-Aldrich, G4251) solution was prepared in 100 mM Tris (pH 7.6) and added to the peptide solution.
The reaction was followed with UPLC and samples were taken every 15 min 
